Related Experiment Video

Updated: Jul 2, 2025

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K

Prostate artery embolization using liquid embolic agents: Is it the future or just a trend?

Tom Boeken1

  • 1Université Paris Cité, Faculté de Médecine, 75006 Paris, France; Department of Vascular and Oncological Interventional Radiology, Hôpital Européen Georges Pompidou, AP-HP, HEKA INRIA, INSERM PARCC U 970, 75015 Paris, France.

Diagnostic and Interventional Imaging
|February 27, 2024
PubMed
Summary

No abstract available in PubMed .

Keywords:
Benign prostatic hyperplasiaLiquid embolic agentsLower urinary tract symptomsProstate artery embolizationRecurrence

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K
Induction of Cerebral Arterial Gas Embolism in Rat06:26

Induction of Cerebral Arterial Gas Embolism in Rat

Published on: October 18, 2024

444

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165